CDC's RSV vaccine recommendations from Pfizer and GSK face review by HHS advisor William "Reyn" Archer III. Read more here.

An FDA panel of experts has recommended approval of Pfizer’s respiratory syncytial virus (RSV) vaccine in a pair of ... s RSVPreF3 jab will come under the scrutiny of the VRBPAC later today ...

The advisory panel to the Centers for Disease Control and Prevention had made recommendations regarding the use of separate ...

The case revolved around whether texts between a top official and a drug company executive counted as a public record that ...

The advisory committee meeting is an important step in the process of readying boosters for the fall and winter season, but ...

Far fewer babies had severe cases of the respiratory illness RSV, in a winter in which a new monoclonal and vaccine became ...

Additional data required by the FDA are the latest evidence of what one analyst described as a “higher bar” for vaccines.

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) has issued new separate recommendations supporting expanded use of Pfizer’s respiratory syncytial ...

Pfizer recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at increased risk. Despite this positive development, Pfizer's shares saw a 2% decline ...

Pfizer currently is the only company with an RSV vaccine to help protect adults aged 60 and older, and adults 18 and older at increased risk of lower respiratory tract disease caused by RSV (RSV ...